Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2021-04-30 | Michael Davidson, MD has served as a director since February 2021. Dr. Davidson was the Founder and former Chief Scientific Officer of Corvidia Therapeutics, which was recently acquired by Novo-Nordisk for $2.1 billion. |
| 2022-04-28 | Michael Davidson, MD, has served as a director since February 2021. Our Board of Directors believes that Dr. Davidson’s medical background and extensive experience in clinical development, as well as his extensive experience as an executive of several biotechnology companies, qualify him to serve on our Board. The Board has determined that Dr. Davidson is an independent director. He serves on the Audit and Compliance Committee and the Compensation Committee. |
| 2023-04-28 | Michael Davidson, MD has served as a director since February 2021. ... Our Board of Directors believes that Dr. Davidson’s medical background and extensive experience in clinical development, as well as his extensive experience as an executive of several biotechnology companies, qualify him to serve on our Board. ... The members of the Audit and Compliance Committee are currently Drs. Almenoff and Davidson and Ms. Hunter. ... The members of the Compensation Committee are currently Ms. Hunter, Dr. Davidson and Mr. Proehl. ... The following table summarizes the compensation paid to non-employee directors for fiscal year ended December 31, 2022: Michael Davidson, MD 57,500 fees earned or paid in cash, 2,607 option awards, total 60,107. |
| 2023-10-27 | Michael Davidson, MD 30,996 * |
| 2024-04-26 | Michael Davidson, MD has served as a director since February 2021. Our Board of Directors believes that Dr. Davidson’s medical background and extensive experience in clinical development, as well as his extensive experience as an executive of several biotechnology companies, qualify him to serve on our Board. The members of the Audit and Compliance Committee are currently Drs. Almenoff and Davidson and Ms. Hunter. The members of the Compensation Committee are currently Ms. Hunter, Dr. Davidson and Mr. Proehl. The following table summarizes the compensation paid to non-employee directors for fiscal year ended December 31, 2023: Michael Davidson, MD 57,500. |
| 2024-09-27 | Michael Davidson, MD 57,500 |
Data sourced from SEC filings. Last updated: 2025-07-01